CRISPR Therapeutics AG Common Shares’ (NASDAQ:CRSP) quiet period is set to end on Monday, November 28th. CRISPR Therapeutics AG Common Shares had issued 4,000,000 shares in its IPO on October 19th. The total size of the offering was $56,000,000 based on an initial share price of $14.00. During CRISPR Therapeutics AG Common Shares’ quiet period, insiders and underwriters that worked on the IPO are prevented from issuing any research reports for the company because of SEC regulations. Following the end of the company’s quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

CRSP has been the subject of several recent research reports. Citigroup Inc. initiated coverage on CRISPR Therapeutics AG Common Shares in a research note on Tuesday, November 15th. They issued a “neutral” rating and a $19.00 price objective for the company. Guggenheim initiated coverage on CRISPR Therapeutics AG Common Shares in a research note on Monday, November 14th. They issued a “buy” rating and a $30.00 price objective for the company. Piper Jaffray Cos. initiated coverage on CRISPR Therapeutics AG Common Shares in a research note on Monday, November 14th. They issued an “overweight” rating and a $21.00 price objective for the company. Finally, Barclays PLC initiated coverage on CRISPR Therapeutics AG Common Shares in a research note on Monday, November 14th. They issued an “overweight” rating and a $22.00 price objective for the company.

CRISPR Therapeutics AG Common Shares (NASDAQ:CRSP) opened at 19.34 on Friday. CRISPR Therapeutics AG Common Shares has a 1-year low of $13.75 and a 1-year high of $23.97. The firm’s market cap is $101.77 million. The stock has a 50 day moving average price of $16.97 and a 200 day moving average price of $16.97.

In other CRISPR Therapeutics AG Common Shares news, major shareholder Corp /De/ Celgene purchased 800,150 shares of the company’s stock in a transaction dated Monday, October 24th. The stock was purchased at an average price of $14.00 per share, for a total transaction of $11,202,100.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Simeon George purchased 66,500 shares of the company’s stock in a transaction dated Monday, October 24th. The shares were acquired at an average price of $14.00 per share, with a total value of $931,000.00. The disclosure for this purchase can be found here.

COPYRIGHT VIOLATION NOTICE: This report was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another site, it was stolen and republished in violation of US and international trademark & copyright laws. The legal version of this report can be accessed at https://www.thecerbatgem.com/2016/11/25/crispr-therapeutics-ag-common-shares-quiet-period-will-end-on-november-28th-nasdaqcrsp.html.

5 Day Chart for NASDAQ:CRSP

Receive News & Stock Ratings for CRISPR Therapeutics AG Common Shares Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics AG Common Shares and related stocks with our FREE daily email newsletter.